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EDITORIAL Open Access
Neutrophil Elastase Inhibitors: A potential
prophylactic treatment option for SARS-
CoV-2-induced respiratory complications?
Mahmoud M. A. Mohamed1†, Ismail Amr El-Shimy2,3† and Muhammad Abdul Hadi4*
As the death toll from the COVID-19 pandemic caused by
SARS-CoV-2 continues to mount globally, scientists,
healthcare agencies, and pharmaceutical companies are try-
ing hard to find a “cure” and devise treatment strategies to
reduce mortality. “Repurposing” existing drugs to fight
COVID-19 remains an important strategy. Since respiratory
failure remains one of the leading causes of death in
COVID-19 patients, in this commentary, we have critically
discussed the potential benefit of neutrophil elastase inhibi-
tors (NEIs) in patients hospitalised with severe COVID-19.
Around one in three COVID-19 patients admitted to a
hospital develop systemic inflammatory conditions such
as cytokine release syndrome (CRS) [1] and acute re-
spiratory distress syndrome (ARDS) [2]. Since lymphocy-
topenia is often reported in severe COVID-19 patients,
it suggests that systemic inflammatory complications, as-
sociated with disease severity and mortality, are likely to
be mediated by leukocytes other than T cells [3]. The
drop in lymphocyte count is accompanied by an increase
in neutrophil count and a decrease in monocytes, eosin-
ophils, and basophils [4, 5], indicating that, together with
lymphocytopenia, increased neutrophil count and
neutrophil-to-lymphocyte ratio may be important pre-
dictors of disease severity in COVID-19 patients [5]. A
recent case study supported this hypothesis [6]. The pa-
tient’s deterioration on day 12 of illness was preceded by
an elevation in his neutrophil count on day 11, while
lymphocytes and monocytes remained low [6]. Given
that there is often a short window between the time of
hospital admission and development of ARDS in severe
cases [3, 6], a rapid prophylactic therapy is warranted to
effectively prevent complications and death.
Neutrophils play a pivotal role in the development of
ARDS through the production of toxic mediators includ-
ing reactive oxygen species and proteases, especially
elastase [7]. Furthermore, neutrophils can produce inter-
leukin 6 (IL-6) in response to viral infections, in particu-
lar single-stranded RNA viruses such as SARS-CoV-2
via a Toll-like receptor 8 (TLR8)-mediated mechanism
[8]. These cells are also important sources of soluble IL-
6 receptors (IL-6R) in the lungs and may contribute to
pathogenic IL-6R trans-signaling in chronic respiratory
diseases [9]. The importance of this kind of signaling for
the development of CRS has been demonstrated in
chimeric antigen receptor T cell (CART)-treated lymph-
oma patients [10]. These studies suggest that increased
neutrophil count can contribute to CRS and lung dam-
age in patients with ARDS. Additionally, elastase se-
creted by these cells is one of the key proteolytic
enzymes shown to activate the spike (S) protein of coro-
naviruses and shift the viral entry to a low pH-
independent route [11].
We advocate the use of NEIs such as sivelestat to alle-
viate neutrophil-induced damage in high-risk COVID-19
patients. Initiation of sivelestat will serve two strategic
purposes; first, it will mitigate the damaging effect of
neutrophil elastase on the lung connective tissue, and
second, it will limit the virus spreading capabilities by
preventing S protein proteolytic activation (Fig. 1). Sive-
lestat is approved in Japan and the Republic of Korea for
the treatment of acute lung injury and ARDS. Although
existing clinical data is somewhat conflicting, the sever-
ity of lung injury remains an important predictor for
treatment outcomes in such patients [12, 13]. Clinical
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trials that reported positive outcomes of sivelestat treatment
in patients with ARDS and ALI had recruited patients mainly
with lung injury score (LIS) < 2.5. On the other hand, trials
reporting negative outcomes particularly the STRIVE study
had recruited patients mainly with LIS > 2.5 [12, 13] empha-
sizing the critical importance of an early intervention with
sivelestat. Notably, patients enrolled in the STRIVE study
were more heterogeneous than the other trials and included
more cases with non-pulmonary organ failures, conditions
that are not relevant to COVID-19 patients [12, 13]. Further-
more, post hoc analysis of patient subgroups from the
STRIVE study with mean LIS < 2.5 and those with systemic
inflammatory response syndrome revealed a positive out-
come of sivelestat on mortality rate and ventilator-free days
[12, 13]. More importantly, the STRIVE study failed to iden-
tify any evidence of drug-related toxicity and did not offer
any plausible explanation for the increase in long-term mor-
tality in sivelestat-treated groups [12].
Although current evidence to support the use of NEIs
in ARDS induced by COVID-19 is lacking, we
hypothesize that early administration of these drugs to
patients with lymphocytopenia and LIS < 2.5 may be of
significant value to prevent disease progression. Future
clinical trials should be designed to evaluate the effect-
iveness of sivelestat in COVID-19 patients admitted to
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